Fusobacterium in colonic flora and molecular features of colorectal carcinoma - PubMed (original) (raw)
. 2014 Mar 1;74(5):1311-8.
doi: 10.1158/0008-5472.CAN-13-1865. Epub 2014 Jan 2.
Eiichiro Yamamoto, Hiromu Suzuki, Reo Maruyama, Woonbok Chung, Judith Garriga, Jaroslav Jelinek, Hiro-o Yamano, Tamotsu Sugai, Byonggu An, Imad Shureiqi, Minoru Toyota, Yutaka Kondo, Marcos R H Estécio, Jean-Pierre J Issa
Affiliations
- PMID: 24385213
- PMCID: PMC4396185
- DOI: 10.1158/0008-5472.CAN-13-1865
Fusobacterium in colonic flora and molecular features of colorectal carcinoma
Tomomitsu Tahara et al. Cancer Res. 2014.
Abstract
Fusobacterium species are part of the gut microbiome in humans. Recent studies have identified overrepresentation of Fusobacterium in colorectal cancer tissues, but it is not yet clear whether this is pathogenic or simply an epiphenomenon. In this study, we evaluated the relationship between Fusobacterium status and molecular features in colorectal cancers through quantitative real-time PCR in 149 colorectal cancer tissues, 89 adjacent normal appearing mucosae and 72 colonic mucosae from cancer-free individuals. Results were correlated with CpG island methylator phenotype (CIMP) status, microsatellite instability (MSI), and mutations in BRAF, KRAS, TP53, CHD7, and CHD8. Whole-exome capture sequencing data were also available in 11 cases. Fusobacterium was detectable in 111 of 149 (74%) colorectal cancer tissues and heavily enriched in 9% (14/149) of the cases. As expected, Fusobacterium was also detected in normal appearing mucosae from both cancer and cancer-free individuals, but the amount of bacteria was much lower compared with colorectal cancer tissues (a mean of 250-fold lower for Pan-fusobacterium). We found the Fusobacterium-high colorectal cancer group (FB-high) to be associated with CIMP positivity (P = 0.001), TP53 wild-type (P = 0.015), hMLH1 methylation positivity (P = 0.0028), MSI (P = 0.018), and CHD7/8 mutation positivity (P = 0.002). Among the 11 cases where whole-exome sequencing data were available, two that were FB-high cases also had the highest number of somatic mutations (a mean of 736 per case in FB-high vs. 225 per case in all others). Taken together, our findings show that Fusobacterium enrichment is associated with specific molecular subsets of colorectal cancers, offering support for a pathogenic role in colorectal cancer for this gut microbiome component.
©2014 AACR
Figures
Fig.1
Over-representation of F. nucleatum (left) and pan-fusobacterium (right) in CRC tissues relative to adjacent normal colonic mucosa in 89 paired cases. Statistical analysis was performed using the Wilcoxon signed-rank test.
Fig. 2
Distribution of Fusobacterium in CRC patients (n=149). The cases were ranked according to the amount of pan-fusobacterium (right=high amount, left=low amount). Note that all F. nucleatum high cases (n=8) were included in pan-fusobacterium high cases (n=14) and there is clear separation of FB high group (n=14, 9.4%) and FB low/negative group (n=135, 90.6%). Red, CIMP1, MLH1 methylated, BRAF, KRAS and TP53 mutated; blue, CIMP2; grey CIMP-negative, MLH1 unmethylated, BRAF, KRAS and TP53 wild type; white, not determined;
Fig. 3
Number of mutated genes determined by whole exome sequencing analysis in 11 CRCs. (2 FB-high, 6 FB-low/negative CIMP1 and 3 FB-low/negative CIMP2/CIMP-negative). Statistical analysis was performed using One-way ANOVA.
Similar articles
- Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Ogino S, et al. J Pathol. 2006 Oct;210(2):147-54. doi: 10.1002/path.2030. J Pathol. 2006. PMID: 16850502 - Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.
Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H, Yoshii S, Takenouchi T, Hasegawa T, Okita K, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Ito M, et al. Int J Cancer. 2015 Sep 15;137(6):1258-68. doi: 10.1002/ijc.29488. Epub 2015 Mar 13. Int J Cancer. 2015. PMID: 25703934 - Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.
Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR. Tahara T, et al. Gastroenterology. 2014 Feb;146(2):530-38.e5. doi: 10.1053/j.gastro.2013.10.060. Epub 2013 Nov 6. Gastroenterology. 2014. PMID: 24211491 Free PMC article. - Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Nosho K, et al. World J Gastroenterol. 2016 Jan 14;22(2):557-66. doi: 10.3748/wjg.v22.i2.557. World J Gastroenterol. 2016. PMID: 26811607 Free PMC article. Review. - Fusobacterium's link to colorectal neoplasia sequenced: A systematic review and future insights.
Hussan H, Clinton SK, Roberts K, Bailey MT. Hussan H, et al. World J Gastroenterol. 2017 Dec 28;23(48):8626-8650. doi: 10.3748/wjg.v23.i48.8626. World J Gastroenterol. 2017. PMID: 29358871 Free PMC article. Review.
Cited by
- Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V, Masi G. Borelli B, et al. Cancers (Basel). 2022 Oct 11;14(20):4974. doi: 10.3390/cancers14204974. Cancers (Basel). 2022. PMID: 36291761 Free PMC article. Review. - The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.
Xiao Y, Freeman GJ. Xiao Y, et al. Cancer Discov. 2015 Jan;5(1):16-8. doi: 10.1158/2159-8290.CD-14-1397. Cancer Discov. 2015. PMID: 25583798 Free PMC article. - The role of microbiomes in gastrointestinal cancers: new insights.
Yarahmadi A, Afkhami H. Yarahmadi A, et al. Front Oncol. 2024 Feb 1;13:1344328. doi: 10.3389/fonc.2023.1344328. eCollection 2023. Front Oncol. 2024. PMID: 38361500 Free PMC article. Review. - A prospective, single-centre, randomized, double-blind controlled study protocol to study whether long-term oral metronidazole can effectively reduce the incidence of postoperative liver metastasis in patients with colorectal cancer.
Gao RQ, Mo ZC, Zhou HK, Yu PF, Wang WD, Dong DH, Yang XS, Li XH, Ji G. Gao RQ, et al. Trials. 2023 Dec 4;24(1):786. doi: 10.1186/s13063-023-07628-y. Trials. 2023. PMID: 38049888 Free PMC article. - Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa.
Sun A, Park P, Cole L, Vaidya H, Maegawa S, Keith K, Calendo G, Madzo J, Jelinek J, Jobin C, Issa JJ. Sun A, et al. Epigenetics. 2023 Dec;18(1):2160568. doi: 10.1080/15592294.2022.2160568. Epub 2022 Dec 26. Epigenetics. 2023. PMID: 36572998 Free PMC article.
References
- Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011;13:25–36. - PubMed
- Swidsinski A, Dörffel Y, Loening-Baucke V, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011;60:34–40. - PubMed
- Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17:1971–1978. - PubMed
- Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol. 2002;97:939–946. - PubMed
- Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002;17:849–853. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA016672/CA/NCI NIH HHS/United States
- R01 CA158112/CA/NCI NIH HHS/United States
- CA158112/CA/NCI NIH HHS/United States
- R01 CA098006/CA/NCI NIH HHS/United States
- CA098006/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous